Subscribe
shutterstock_1983054248_jhvephoto
JHVEphoto / Shutterstock.com
11 October 2022EuropeSarah Speight

Teva breached antitrust rules over Copaxone, says EU

European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Big Pharma
Teva secures victory in iron overload treatment dispute
17 November 2022   Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.
Big Pharma
Teva and Apotex prevail in sleep drug dispute
11 May 2023   The dispute centred on a treatment that helps people adjust their circadian rhythm | Path now clear for generic drug makers to unveil biosimilar versions of the drug.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Big Pharma
Teva secures victory in iron overload treatment dispute
17 November 2022   Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.
Big Pharma
Teva and Apotex prevail in sleep drug dispute
11 May 2023   The dispute centred on a treatment that helps people adjust their circadian rhythm | Path now clear for generic drug makers to unveil biosimilar versions of the drug.

More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Big Pharma
Teva secures victory in iron overload treatment dispute
17 November 2022   Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.
Big Pharma
Teva and Apotex prevail in sleep drug dispute
11 May 2023   The dispute centred on a treatment that helps people adjust their circadian rhythm | Path now clear for generic drug makers to unveil biosimilar versions of the drug.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent